2021
-
View from the Trenches: Key clinical practice takeaways from #SABCS21
The final session of SABCS 2021 highlighted some of the most important breast cancer results from the meeting and put the findings into context for day-to-day clinical practice.
-
Year in Review: Panelists summarize key findings in breast cancer research in 2021
A panel of experts discussed some of the latest advances in early and advanced breast cancer, basic science, and translational research during the special session Year in Review on Friday.
-
Plenary lecturer highlights advancements, emerging treatments in TNBC
In her plenary lecture on Friday, medical oncologist Lisa A. Carey, MD, ScM, discussed triple negative breast cancer, including advancements in treatment options and implications for population health.
-
Researcher reviews progression of genetic profiling during plenary lecture
During the plenary lecture on Thursday, Mitchell Dowsett, PhD, FMedSci, looked at genetic profiling from early research to clinical utility and addressed clinically critical questions that have yet to be answered.
-
Studies looking at impact of race on breast cancer severity and outcomes presented at #SABCS21
Friday’s General Session included two studies into race as a factor in the incidence, severity, and treatment outcomes of breast cancer.
-
AACR Outstanding Investigator Award: Precision medicine a work in progress
Fabrice André, MD, PhD, received this year’s AACR Outstanding Investigator Award for Breast Cancer Research for his work helping to establish the concept of using real-time, high-throughput genomic analysis of cancer biopsies to identify potential therapeutic targets.
-
Special session explores how to build trust in science, healthcare
Lori Wilson, MD, and Charles Perou, PhD, gave keynote presentations during a special session focused on advancing health equity through building trust and improving access to care and clinical trials.
-
Data from PADA-1 and PHOEBE trials presented on Thursday at #SABCS21
Thursday’s General Session included findings from a study looking at fulvestrant plus palbociclib for HR+ breast cancer and results of a study of pyrotinib plus capecitabine for previously treated HER2+ metastatic breast cancer.
-
AACR distinguished lecturer discusses cell cycle discoveries leading to targeted therapies
Helen M. Piwnica-Worms, PhD, discussed her journey from basic research to translational trials during the 2021 AACR Distinguished Lectureship in Breast Cancer Research on Thursday.
-
Debate will tackle 1-week versus 3-week whole breast radiation for early-stage breast cancer
During a debate this morning, Charlotte Coles, MBChB, PhD, will present the “Pro” argument, and Julia White, MD, will present the “Con” argument on the adoption of a new schedule for whole breast radiotherapy.